Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 37

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018

Summary

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Transglutaminase 2 (TG2) is a member of the transglutaminase family that catalyzes calcium-dependent posttranslational modification of proteins by inserting highly stable isopeptide bonds between polypeptide chains or by conjugating polyamines to proteins. TG2 also exhibits GTPase activity and can serve as a signal-transduction G protein.

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Gastrointestinal, Oncology, Infectious Disease and Respiratory which include indications Celiac Disease, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Burkholderia Infections, Cystic Fibrosis, Pseudomonas aeruginosa Infections and Renal Cell Carcinoma.

The latest report Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13)

- The report reviews Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics and enlists all their major and minor projects

- The report assesses Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Overview
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Companies Involved in Therapeutics Development
Catabasis Pharmaceuticals Inc
Zedira GmbH
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Drug Profiles
Angiocidin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-5571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-201782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Dormant Products
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2017: Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
Jun 02, 2017: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
May 02, 2017: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
Jan 05, 2017: Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry
Nov 30, 2016: Zedira receives funding from the German Government for the development of transglutaminase inhibitor ZED-1227 for the treatment of diabetic nephropathy
Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-5571 at Investor Day
Oct 27, 2016: Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
Oct 20, 2016: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
Jul 01, 2016: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
Oct 20, 2015: Additional subsidy funding for clinical development of a celiac disease drug
Mar 02, 2015: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
Dec 07, 2012: Temple University Professor Presents Pre-Clinical Data Of Angiocidin In Leukemia At ASH 2012
Mar 19, 2009: Numerate Awarded Phase 1 NIH Grant To Support Design Of New Therapies For Celiac Disease
Jul 15, 2008: Tumor-Inhibiting Protein Discovered By Temple Researchers Could Be Effective In The Treatment Of Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Catabasis Pharmaceuticals Inc, H2 2018
Pipeline by Zedira GmbH, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • 2018-2023 Global Melanoma Drugs Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Melanoma Drugs market for 2018-2023. Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the mal......
  • 2018-2023 Global Medication Management System Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 139
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Medication Management System market for 2018-2023. Medication management systems ensure tracking and validation of the medication administered to patients at all points of care. These systems help healthcare organizations to minimize medical errors occurring in the healthcare environment. Over the next five years, LPI(LP Information) projects......
  • 2018-2023 Global Drugs for Melanoma Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 137
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Melanoma market for 2018-2023. Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the......
  • 2018-2023 Global Membrane Filter Cartridge Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Membrane Filter Cartridge market for 2018-2023. Membrane cartridge filters are typically constructed with a large surface area of thin polymeric filter media, pleated to fit into a relatively small assembly. This results in a filter that offers high flow rates and low pressure losses. These filters are ideal for use in critical applications in the Pharmaceu......
  • 2018-2023 Global Meningococcal Disease Treatment Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Meningococcal Disease Treatment market for 2018-2023. Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk ......
  • 2018-2023 Global Meningococcal Disease Drugs Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Meningococcal Disease Drugs market for 2018-2023. Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of d......
  • 2018-2023 Global Merkel Cell Carcinoma Treatment Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 158
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Merkel Cell Carcinoma Treatment market for 2018-2023. Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs ......
  • 2018-2023 Global Microbial Fermentation Technology Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Microbial Fermentation Technology market for 2018-2023. Fermentation technology is a field which involves the use of microorganisms and enzymes for production of compounds which have application in the energy, material, pharmaceutical, chemical and the food industries. Though fermentation processes are used for generations for the requirement for sustainabl......
  • 2018-2023 Global Culture Media of Microbiology Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 137
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Culture Media of Microbiology market for 2018-2023. A microbiological culture or microbial culture is a process of multiplying microbial organisms. Through allowing them to reproduce in predetermined lifestyle media under controlled laboratory situations. Microbial cultures are used to decide the form of organism, its abundance within the pattern being test......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs